Matches in Nanopublications for { ?s ?p "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 18 of
18
with 100 items per page.
- NP647357.RAUh1yvsCH4TFMxfAf8JFTmLNyxuQuX1l-f20daMtJgcs130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647357.RAUh1yvsCH4TFMxfAf8JFTmLNyxuQuX1l-f20daMtJgcs130_provenance.
- NP726538.RAX7pumjxD8uLt6LespEx_LXleekdM5gpbJdaElExoSUU130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP726538.RAX7pumjxD8uLt6LespEx_LXleekdM5gpbJdaElExoSUU130_provenance.
- assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP370612.RAa3rN8B01q1efIhB9R2O0wGouDEvmtWxxb84pETn4phc130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP370612.RAa3rN8B01q1efIhB9R2O0wGouDEvmtWxxb84pETn4phc130_provenance.
- NP609422.RAOiV5HY9Q5wvKoovfPN8vIfVJqzFk1zxgy1aTN9UO4-o130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609422.RAOiV5HY9Q5wvKoovfPN8vIfVJqzFk1zxgy1aTN9UO4-o130_provenance.
- NP380473.RAAwhRFC09lJt3SMKFwFLUqTU9Wg-TEGT6eVPyO7DG8Xs130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380473.RAAwhRFC09lJt3SMKFwFLUqTU9Wg-TEGT6eVPyO7DG8Xs130_provenance.
- NP650553.RAeuzV3OO0hunA6z0ar3If5SBtgX1L5JsxOQciGTDNYfo130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650553.RAeuzV3OO0hunA6z0ar3If5SBtgX1L5JsxOQciGTDNYfo130_provenance.
- NP368410.RAgFB8q98Yx_e4bdFSnr3cCD9lhLumN-JYe8rtoG7sTbE130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP368410.RAgFB8q98Yx_e4bdFSnr3cCD9lhLumN-JYe8rtoG7sTbE130_provenance.
- NP378748.RAikaxLYSB1QH1isvCs5ZlYo19kky-0TrK3RQDruJw2Yo130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378748.RAikaxLYSB1QH1isvCs5ZlYo19kky-0TrK3RQDruJw2Yo130_provenance.
- NP650551.RAsVX971tkaqmAPfqZmqStLeyM9C6_zO1Rjrn-w9V6Z9Y130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650551.RAsVX971tkaqmAPfqZmqStLeyM9C6_zO1Rjrn-w9V6Z9Y130_provenance.
- NP369835.RAHNd9IP3BsVhRevXOQgPZK6P4NhIWhhSO12sKH6ELR04130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP369835.RAHNd9IP3BsVhRevXOQgPZK6P4NhIWhhSO12sKH6ELR04130_provenance.
- NP650549.RAGGbb0WQKnqb9UtFRh58g74Ky0rOvSL1fOUjusEAeAHk130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650549.RAGGbb0WQKnqb9UtFRh58g74Ky0rOvSL1fOUjusEAeAHk130_provenance.
- NP650550.RAGRzJ-Bx1hrSf77jvyKPba8o72615SaCVr3ofiwPkFwY130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650550.RAGRzJ-Bx1hrSf77jvyKPba8o72615SaCVr3ofiwPkFwY130_provenance.
- NP650552.RA6LRI48xbwFsiTTxqhbDGdcbVKbbttf8m1KmKspRkMIw130_assertion description "[In conclusion, high level amplification of HER-2/neu or EGFR is infrequent in endometrial cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650552.RA6LRI48xbwFsiTTxqhbDGdcbVKbbttf8m1KmKspRkMIw130_provenance.